Skip to main content
Top
Gepubliceerd in:

02-03-2021

Health state utility and quality of life measures in patients with chronic myeloid leukemia in France

Auteurs: Foulon S, Cony-Makhoul P, Guerci-Bresler A, Daban M, Kapso R, Tubert-Bitter P, Bonastre J

Gepubliceerd in: Quality of Life Research | Uitgave 7/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of chronic myeloid leukemia (CML). We aimed to assess health state utility and quality of life (QoL) in French patients with CML in real-life setting, to study the determinants of utility score and to compare health-related QoL values to general population norms.

Methods

We conducted a cross-sectional study in 412 patients with CML. Data were collected by electronic survey. Three patient-reported outcomes questionnaires were used: EORTC QLQ-C30, EORTC QLQ-CML24 and EuroQol EQ-5D-3L. Health state utility values were computed using the French value set. We computed deviations from reference norms from the general population. We studied the determinants of health utility score using multiple regression models.

Results

The mean utility score (SD) was 0.72 (0.25) in the chronic phase and 0.84 (0.21) in treatment-free remission, with marked variations by gender. Patients with CML had a deviation from the reference norm of −0.15 on average (SD: 0.25). In terms of QoL, social functioning, role functioning and cognitive functioning were notably impacted with a mean difference of −16.0, −13.1 and −11.7 respectively. Fatigue, dyspnea and pain were the symptoms with the highest deviation from general population norms (mean difference of 20.6, 14.0 and 8.3 respectively). In the multiple regression analysis, fatigue was the most important independent predictor of the utility score.

Conclusion

Although TKIs prevent the disease from progressing and even allow remission without treatment, QoL in patients with CML is notably altered. The utility scores deteriorate with CML symptoms.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
5.
go back to reference Bower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T.M.-L. (2016). Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34(24), 2851–2857. https://doi.org/10.1200/JCO.2015.66.2866.CrossRef Bower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T.M.-L. (2016). Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34(24), 2851–2857. https://​doi.​org/​10.​1200/​JCO.​2015.​66.​2866.CrossRef
7.
go back to reference Rea, D., Ame, S., Berger, M., Cayuela, J.-M., Charbonnier, A., Coiteux, V., et al. (2018). Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer, 124(14), 2956–2963. https://doi.org/10.1002/cncr.31411.CrossRefPubMed Rea, D., Ame, S., Berger, M., Cayuela, J.-M., Charbonnier, A., Coiteux, V., et al. (2018). Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer, 124(14), 2956–2963. https://​doi.​org/​10.​1002/​cncr.​31411.CrossRefPubMed
9.
go back to reference Hahn, E. A., Glendenning, G. A., Sorensen, M. V., Hudgens, S. A., Druker, B. J., Guilhot, F., et al. (2003). Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21(11), 2138–2146. https://doi.org/10.1200/JCO.2003.12.154.CrossRef Hahn, E. A., Glendenning, G. A., Sorensen, M. V., Hudgens, S. A., Druker, B. J., Guilhot, F., et al. (2003). Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21(11), 2138–2146. https://​doi.​org/​10.​1200/​JCO.​2003.​12.​154.CrossRef
16.
go back to reference Phillips, K. M., Pinilla-Ibarz, J., Sotomayor, E., Lee, M. R., Jim, H. S. L., Small, B. J., et al. (2013). Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 21(4), 1097–1103. https://doi.org/10.1007/s00520-012-1630-5.CrossRef Phillips, K. M., Pinilla-Ibarz, J., Sotomayor, E., Lee, M. R., Jim, H. S. L., Small, B. J., et al. (2013). Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 21(4), 1097–1103. https://​doi.​org/​10.​1007/​s00520-012-1630-5.CrossRef
17.
go back to reference Reed, S. D., Anstrom, K. J., Ludmer, J. A., Glendenning, G. A., & Schulman, K. A. (2004). Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 101(11), 2574–2583. https://doi.org/10.1002/cncr.20694.CrossRefPubMed Reed, S. D., Anstrom, K. J., Ludmer, J. A., Glendenning, G. A., & Schulman, K. A. (2004). Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 101(11), 2574–2583. https://​doi.​org/​10.​1002/​cncr.​20694.CrossRefPubMed
18.
go back to reference Labeit, A. M., Copland, M., Cork, L. M., Hedgley, C., Foroni, L., Osborne, W. L., et al. (2015). Assessment of quality of life in the NCRI spirit 2 study comparing imatinib with dasatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia. Blood, 126(23), 4024.CrossRef Labeit, A. M., Copland, M., Cork, L. M., Hedgley, C., Foroni, L., Osborne, W. L., et al. (2015). Assessment of quality of life in the NCRI spirit 2 study comparing imatinib with dasatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia. Blood, 126(23), 4024.CrossRef
22.
go back to reference EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands), 16(3), 199–208.CrossRef EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands), 16(3), 199–208.CrossRef
23.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRef Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRef
24.
go back to reference Efficace, F., Baccarani, M., Breccia, M., Saussele, S., Abel, G., Caocci, G., et al. (2014). International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 23(3), 825–836. https://doi.org/10.1007/s11136-013-0523-5.CrossRef Efficace, F., Baccarani, M., Breccia, M., Saussele, S., Abel, G., Caocci, G., et al. (2014). International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 23(3), 825–836. https://​doi.​org/​10.​1007/​s11136-013-0523-5.CrossRef
27.
go back to reference Szende, A., Janssen, B., & Cabases, J. (2014). Self-reported population health: An international perspective based on EQ-5D. Netherlands: Springer.CrossRef Szende, A., Janssen, B., & Cabases, J. (2014). Self-reported population health: An international perspective based on EQ-5D. Netherlands: Springer.CrossRef
28.
go back to reference Liegl, G., Petersen, M. A., Groenvold, M., Aaronson, N. K., Costantini, A., Fayers, P. M., et al. (2019). Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core. European Journal of Cancer (Oxford, England: 1990), 107, 133–141. https://doi.org/10.1016/j.ejca.2018.11.023.CrossRef Liegl, G., Petersen, M. A., Groenvold, M., Aaronson, N. K., Costantini, A., Fayers, P. M., et al. (2019). Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core. European Journal of Cancer (Oxford, England: 1990), 107, 133–141. https://​doi.​org/​10.​1016/​j.​ejca.​2018.​11.​023.CrossRef
29.
go back to reference Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(1), 89–96. https://doi.org/10.1200/JCO.2010.28.0107.CrossRef Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(1), 89–96. https://​doi.​org/​10.​1200/​JCO.​2010.​28.​0107.CrossRef
32.
34.
36.
go back to reference Zulbaran-Rojas, A., Lin, H.-K., Shi, Q., Williams, L. A., George, B., Garcia-Manero, G., et al. (2018). A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Medicine, 7(11), 5457–5469. https://doi.org/10.1002/cam4.1808.CrossRefPubMedPubMedCentral Zulbaran-Rojas, A., Lin, H.-K., Shi, Q., Williams, L. A., George, B., Garcia-Manero, G., et al. (2018). A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Medicine, 7(11), 5457–5469. https://​doi.​org/​10.​1002/​cam4.​1808.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Health state utility and quality of life measures in patients with chronic myeloid leukemia in France
Auteurs
Foulon S
Cony-Makhoul P
Guerci-Bresler A
Daban M
Kapso R
Tubert-Bitter P
Bonastre J
Publicatiedatum
02-03-2021
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 7/2021
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-02794-5